CGT-6321

**CGT-6321** is an investigational **FGFR/VEGFR tyrosine kinase inhibitor** being developed by **CGeneTech** for the treatment of **solid tumors**. Based on the company pipeline information provided, it is a targeted antineoplastic program with dual activity against fibroblast growth factor receptor and vascular endothelial growth factor receptor signaling, a mechanism intended to inhibit tumor-cell proliferative signaling and tumor angiogenesis. The program appears to be in the **IND or IND-enabling stage**, and no proprietary non-code name, formulation, dosage form, or route of administration was explicitly disclosed in the provided source material.